Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.


Serval ID
Article: article from journal or magazin.
Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.
European Journal of Gastroenterology and Hepatology
Melin P., Chousterman M., Fontanges T., Ouzan D., Rotily M., Lang J.P., Marcellin P., Cacoub P.
Working group(s)
CheObs Study Group
Alric L., Andreani T., Antoni M., Arpurt JP., Bacq Y., Bailly F., Balian A., Ballorain X., Bapin C., Barbare JC., Barbereau D., Bardou M., Baroni JL., Barriere E., Bary M., Bellaiche G., Bellon S., Benali S., Benhaim S., Beorchia S., Bernard P., Bernard-chabert B., Besson I., Bettan L., Beurton I., Bianchi D., Blanc P., Blanchi A., Bommelaer G., Bonaventure C., Bonny C., Bottafridlund D., Boulant J., Boulay G., Bourliere M., Boyer N., Bramli S., Bronowicki JP., Brung-lefebvre M., Calmus Y., Canva JY., Canvadelcambre V., Cassigneul J., Castera L., Causse X., Cayla JM., Chevalier C., Chevassus P., Chiari R., Chryssostalis A., Combis JM., Conti F., Corcos D., Croizet O., Cuillerier E., Czernichow B., D'Alteroche L., Danielou H., Danne O., Dao MT., D'Arondel De Haye C., Delasalle P., Deltenre P., Denis J., Dernaika S., Desmorat H., Doll J., Doumet S., Duclos-Vallee JC., Duffaut M., Elfadel S., Eschmann G., Eugene C., Faroux R., Fartoux Heymann L., Fatisse A., Filoche B., Fleury A., Fouchard-hubert I., Foucher J., Fratte S., Garcia V., Gargot D., Gaudin JL., Giuily N., Goria O., Gourlaouen A., Grimaldi S., Guillemard C., Guillygomarc'h A., Guyader D., Habersetzer F., Hachemane S., Haddad N., Hagege H., Haioun N., Hanslik B., Hatem C., Hemery ML., Hervio P., Hezode C., Hilleret£££Noëlle£££ N. , Hillon P., Hyrailles V., Jacques JP., Kitmacher P., Landau A., Lapoile E., Larrey D., Larroque O., Le Calvez S., Lebray P., Lejeune O., Lemoine A., Levy S., Longo F., Loustaud Ratti V., Louvet H., Lucidarme D., Mathieu-chandelier C., Mathurin P., Metivier S., Miguet JP., Minello A., Mion F., Moussalli J., Nalet B., Nousbaum JB., Oberti F., Oules V., Pageaux GP., Payen JL., Pilette C., Pillon D., Portal I., Pouderoux P., Raffanel C., Ramgoolam B., Randl K., Ratziu V., Regimbeau C., Remy AJ., Renou C., Riachi G., Ribard D., Ribiere O., Richardet JP., Ripault MP., Roche B., Roche C., Rogeaux O., Rollux R., Rosa I., Roudotthoraval F., Saliba F., Sapey T., Savary O., Scalone O., Schnee M., Schoeny M., Serfaty L., Serpaggi J., Sgro E., Si Ahmed SN. , Souvignet C., Szostak-talbodec N., Tellaroli JC., Thabut D., Tordjman G., Trepo C., Truchi R., Vanlemmens C., Vitte R., Zarski JP.
1473-5687 (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
OBJECTIVE: Injection drug users are often excluded from hepatitis C virus (HCV) treatment. This study compares sustained virological response, adherence, and quality of life in patients with or without a history of illicit drug use in routine clinical practice.
METHODS: This is a post-hoc analysis of a prospective, observational study conducted in 1860 patients who received peginterferon alpha-2b/ribavirin combination therapy. Nondrug users (NDUs) were defined as patients without a history of drug addiction; former drug users (FDUs) as patients who had stopped using illicit drugs or opioid maintenance therapy and active drug users (ADUs) as patients using illicit drugs or on opioid maintenance therapy. Virological response, adherence, and the health-related quality of life were assessed by the measure of HCV RNA in the serum, self-report and 36-item short-form health survey Questionnaire, respectively.
RESULTS: The analyzed population included 1038 (56%) NDUs, 578 (31%) FDUs, and 244 (13%) ADUs. About 85% of ADUs were on opioid maintenance therapy and 25% used illicit drugs. Although ADUs had a more chaotic lifestyle and more psychiatric disorders, sustained virological response of ADUs (58%) did not differ from that of NDUs (49%) and FDUs (51%) (P=0.133). Adherence rates were 39% in NDUs and FDUs, and 37% in ADUs (P=0.883). Health-related quality of life was improved in the three groups after the end of treatment.
CONCLUSION: Our study suggests that HCV therapy in ADUs on opioid maintenance therapy is as effective as in other HCV patients. The effectiveness of HCV therapy in illicit drug users needs to be evaluated in further studies.
Analgesics, Opioid/administration & dosage, Antiviral Agents/administration & dosage, Cohort Studies, Drug Therapy, Combination, Hepatitis C, Chronic/complications, Hepatitis C, Chronic/drug therapy, Interferon-alpha/administration & dosage, Medication Adherence, Polyethylene Glycols/administration & dosage, Prospective Studies, Quality of Life, Questionnaires, Recombinant Proteins, Ribavirin/administration & dosage, Substance-Related Disorders/complications, Substance-Related Disorders/drug therapy, Treatment Outcome
Web of science
Create date
06/12/2013 10:10
Last modification date
20/08/2019 16:23
Usage data